Maxwell Biomedical Email Formats

About Maxwell Biomedical

Rhythm360: The First-Ever CRT for the Atrium—Restoring Atrial Function in HFpEF Without Destruction MaxWell Biomedical is creating a new category in cardiac rhythm management (CRM) with Rhythm360, the first implantable system designed to restore atrial synchrony and sinus rhythm non-destructively—directly addressing the root cause of electromechanical dysfunction in patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). The Unmet Need: AF and HFpEF often coexist, creating a cycle of electrical and mechanical disruption that impairs atrial contraction, worsens congestion, reduces cardiac filling, and leads to poor outcomes. No approved device today restores atrial rhythm and function for these patients. Ablation, while common, fails to restore atrial mechanics and carries risk of recurrence and tissue damage. Drug therapies are often limited by efficacy, durability, and patient tolerance. The Rhythm360 Breakthrough: Rhythm360 introduces Spatial Resynchronization Therapy (SRT)—an AI-driven, non-destructive, multi-site pacing platform that: Terminates AF in real time without ablation Restores biatrial synchrony to enhance diastolic function and cardiac output Enables repeatable, personalized rhythm control—without scar or sedation Why It Matters: Just as cardiac resynchronization therapy (CRT) transformed outcomes by restoring ventricular synchrony in HFrEF, Rhythm360 is the first-ever CRT for the atrium, bringing this paradigm to patients with HFpEF. By preserving tissue, restoring function, and improving hemodynamics, Rhythm360 offers the first rhythm control solution purpose-built for this rapidly growing, high-risk population. MaxWell’s platform paves the way for scalable, atrial-based therapies across multiple indications—including AF-HFpEF, post-operative AF, and future wearable-guided rhythm management. Preserve. Resynchronize. Transform Care.

View contact profiles from Maxwell Biomedical